AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
oleh: Jordi Bertran-Alamillo, Valérie Cattan, Marie Schoumacher, Jordi Codony-Servat, Ana Giménez-Capitán, Frédérique Cantero, Mike Burbridge, Sonia Rodríguez, Cristina Teixidó, Ruth Roman, Josep Castellví, Silvia García-Román, Carles Codony-Servat, Santiago Viteri, Andrés-Felipe Cardona, Niki Karachaliou, Rafael Rosell, Miguel-Angel Molina-Vila
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2019-04-01 |
Deskripsi
Non-small cell lung cancer with EGFR mutations are known to develop resistance to EGFR tyrosine kinase inhibitors. Here, the authors show AURKB activation to be associated with resistance in EGFR mutant lung cancer cells, and that AURKB is a therapeutic target in resistant tumours that lack the p.T790M or other acquired mutations.